Evolent Health Inc. (NYSE:EVH) shares gapped up prior to trading on Monday . The stock had previously closed at $24.83, but opened at $24.91. Evolent Health shares last traded at $25.28, with a volume of 35,305 shares traded.

Several research firms have weighed in on EVH. Canaccord Genuity began coverage on shares of Evolent Health in a research report on Wednesday, June 1st. They issued a “buy” rating on the stock. FBR & Co reiterated a “buy” rating on shares of Evolent Health in a research report on Saturday, May 14th. Zacks Investment Research cut shares of Evolent Health from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th. Finally, Leerink Swann reissued a “buy” rating and issued a $20.00 price objective on shares of Evolent Health in a research note on Monday, May 16th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $22.50.

The company’s market capitalization is $1.51 billion. The firm’s 50-day moving average is $24.04 and its 200-day moving average is $15.71.

Evolent Health (NYSE:EVH) last released its earnings results on Thursday, August 4th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.04. The business had revenue of $56.50 million for the quarter, compared to the consensus estimate of $51.96 million. During the same quarter in the previous year, the company earned ($0.95) earnings per share. The firm’s revenue for the quarter was up 443.3% on a year-over-year basis. Equities analysts predict that Evolent Health Inc. will post ($0.54) EPS for the current fiscal year.

An institutional investor recently raised its position in Evolent Health stock. Wells Fargo & Company MN boosted its position in shares of Evolent Health Inc. (NYSE:EVH) by 22.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 808,909 shares of the company’s stock after buying an additional 145,685 shares during the period. Wells Fargo & Company MN owned approximately 1.37% of Evolent Health worth $9,796,000 at the end of the most recent quarter.

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.